Health Canada drug identification number

DIN 02559617 — BLENREP 70 MG

BLENREP is a powder for solution of Belantamab mafodotin marketed by GLAXOSMITHKLINE INC. The full Belantamab mafodotin monograph covers indications, dosing, interactions and counselling for every strength and manufacturer.

DIN
02559617
Brand name
BLENREP
Active ingredient
Belantamab mafodotin
Strength
70 MG
Dosage form
POWDER FOR SOLUTION
Route
INTRAVENOUS
Manufacturer
GLAXOSMITHKLINE INC
Health Canada status
MARKETED
Drug class
BCMA-targeted antibody-drug conjugate (antineoplastic agent)

Product data from the Health Canada Drug Product Database, synced . Verify the live status at Health Canada.

Other Belantamab mafodotin products

DINBrandStrengthFormManufacturerStatus
02559625 BLENREP 100 MG POWDER FOR SOLUTION GLAXOSMITHKLINE INC MARKETED

Rejoining the server...

Rejoin failed... trying again in seconds.

Failed to rejoin.
Please retry or reload the page.

The session has been paused by the server.

Failed to resume the session.
Please retry or reload the page.